Healthcare Industry News: total hip replacement
News Release - December 12, 2007
Biomet Launches Hip Technologies to Address Demand for Minimally Invasive Bone-Conserving ImplantsWARSAW, Ind.--(HSMN NewsFeed)--Biomet, Inc. announced today that Biomet Orthopedics is launching two innovative hip stems, the Taperloc® Microplasty™ Stem and the Balance® Microplasty™ Stem, to address the demand for minimally invasive bone-conserving total hip implants. Furthermore, these options offer conservative alternatives to femoral resurfacing devices that typically cannot be implanted using minimally invasive techniques.
The Taperloc® Microplasty™ Stem was designed to build on the extremely successful 20-year heritage of the clinically proven Taperloc® Hip System, while incorporating new design features to better address minimally invasive techniques. Utilizing Biomet’s clinically proven porous plasma spray coating, the Taperloc® Microplasty™ Stem offers the same flat, tapered wedge design as the conventional Taperloc® Hip System, but provides a shorter stem. The short stem is designed for proximal femoral bone fixation, while preserving more intramedullary bone than traditional length components.
The Balance® Microplasty™ Stem builds on the foundation of the original porous-coated Balance® Hip Stem to incorporate an anatomic “fit and fill” geometry for those surgeons who prefer this type of design philosophy. The primary difference between the minimally invasive stem and the conventional hip stem is the shorter length of the stem, which is designed to preserve bone distally and maintain proximal femoral bone fixation.
Biomet’s President and Chief Executive Officer Jeffrey R. Binder commented, “Our investment in research and development continues to provide us with new and exciting products and technologies, offering surgeons innovative implants such as the Taperloc® and Balance® Microplasty™ Stems. These new hip stems are designed to address the demand for bone-conserving products that can be implanted using a minimally invasive surgical approach, while expanding upon the proven technologies that have provided the broad clinical success of traditional total hip replacement.”
Biomet, Inc. and its subsidiaries design, manufacture, and market products used primarily by musculoskeletal medical specialists in both surgical and non-surgical therapy. Biomet’s product portfolio encompasses reconstructive products, including orthopedic joint replacement devices, bone cements and accessories, autologous therapies and dental reconstructive implants; fixation products, including electrical bone growth stimulators, internal and external orthopedic fixation devices, craniomaxillofacial implants and bone substitute materials; spinal products, including spinal stimulation devices, spinal hardware and orthobiologics; and other products, such as arthroscopy products and softgoods and bracing products. Headquartered in Warsaw, Indiana, Biomet and its subsidiaries currently distribute products in more than 70 countries.
This press release contains certain statements that are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements are qualified by the inherent risks and uncertainties surrounding future expectations generally, and also may materially differ from actual future experience involving any one or more of such statements. Such risks and uncertainties include our ability to develop and market new products and technologies in a timely manner, and the risk factors as set forth from time to time in Biomet’s filings with the SEC. The inclusion of a forward-looking statement herein should not be regarded as a representation by Biomet that Biomet’s objectives will be achieved. Biomet undertakes no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise.
Source: Biomet, Inc
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.